81 related articles for article (PubMed ID: 35840951)
1. Efficacy of Adjuvant Chemotherapy for Stage II/III Nonsmall Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations.
Matsunaga T; Takamochi K; Hattori A; Fukui M; Suzuki K
Thorac Cardiovasc Surg; 2023 Dec; 71(8):664-670. PubMed ID: 36822230
[TBL] [Abstract][Full Text] [Related]
2. Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.
Ludovini V; Flacco A; Bianconi F; Ragusa M; Vannucci J; Bellezza G; Chiari R; Minotti V; Pistola L; Tofanetti FR; Siggillino A; Baldelli E; Sidoni A; Daddi N; Puma F; Varella-Garcia M; Crinò L
Cancer Chemother Pharmacol; 2013 Mar; 71(3):671-80. PubMed ID: 23314677
[TBL] [Abstract][Full Text] [Related]
3. Air bronchogram on chest CT in radiological pure-solid appearance lung cancer: Correlation analysis with genetic pathological features and survival outcomes.
Wang Z; Zhu W; Yang M; Du H; Zhou F; Song N; Wan Z; Zhu J; Li W
Eur J Radiol; 2023 Dec; 169():111194. PubMed ID: 37976762
[TBL] [Abstract][Full Text] [Related]
4. Impact of Waiting Times on Mortality in Advanced Stage Non-Small Cell Lung Cancer: A 10-Year Retrospective Cohort Study in Thailand.
Vichapat V; Chantasartrassamee P; Reungwetwattana T
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3419-3428. PubMed ID: 37898846
[TBL] [Abstract][Full Text] [Related]
5. Intronic variant of EGFR is associated with GBAS expression and survival outcome of early-stage non-small cell lung cancer.
Hong MJ; Lee SY; Choi JE; Kang HG; Do SK; Lee JH; Yoo SS; Lee EB; Seok Y; Cho S; Jheon S; Lee J; Cha SI; Kim CH; Park JY
Thorac Cancer; 2018 Aug; 9(8):916-923. PubMed ID: 29806744
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC.
Pedraz-Valdunciel C; Ito M; Giannoukakos S; Giménez-Capitán A; Molina-Vila MÁ; Rosell R
JTO Clin Res Rep; 2023 Dec; 4(12):100604. PubMed ID: 38162176
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of a consecutive cohort validating an epidermal growth factor receptor mutation as an independent risk factor for postoperative recurrence in lung adenocarcinoma.
Matsumura Y; Hayasaka K; Ohira T; Shiono S; Abe J; Notsuda H; Sakurada A; Suzuki H; Okada Y
Interdiscip Cardiovasc Thorac Surg; 2023 Nov; 37(5):. PubMed ID: 37930012
[TBL] [Abstract][Full Text] [Related]
8. Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring
Kim IA; Hur JY; Kim HJ; Lee SA; Hwang JJ; Kim WS; Lee KY
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298845
[TBL] [Abstract][Full Text] [Related]
9. A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer.
Cao W; Tang Q; Zeng J; Jin X; Zu L; Xu S
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760531
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
11. Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer.
Huang LT; Zhang SL; Han CB; Ma JT
Lung Cancer; 2022 Apr; 166():9-16. PubMed ID: 35151115
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.
Matsumoto Y; Kawaguchi T; Watanabe M; Isa SI; Ando M; Tamiya A; Kubo A; Kitagawa C; Yoshimoto N; Koh Y
BMC Cancer; 2022 Jul; 22(1):775. PubMed ID: 35840951
[TBL] [Abstract][Full Text] [Related]
13. Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Matsumoto Y; Sawa K; Fukui M; Oyanagi J; Yoshimoto N; Suzumura T; Watanabe T; Kaneda H; Mitsuoka S; Asai K; Kimura T; Yamamoto N; Hirata K; Koh Y; Kawaguchi T
Lung Cancer; 2020 Jan; 139():80-88. PubMed ID: 31751804
[TBL] [Abstract][Full Text] [Related]
14. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
[TBL] [Abstract][Full Text] [Related]
15. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
